What is Amgen?
Amgen Inc. is a leading American multinational biotechnology company headquartered in Thousand Oaks, California. Founded in 1980 as Applied Molecular Genetics, Amgen was instrumental in pioneering the biotechnology industry and has consistently remained at the forefront of scientific innovation. The company focuses on developing and delivering innovative human therapeutics. Its enterprise-level funding context indicates a mature operational stage, likely focused on scaling existing successes and pursuing advanced research and development initiatives within the competitive biopharmaceutical landscape.
How much funding has Amgen raised?
Amgen has raised a total of $2B across 2 funding rounds:
Debt
$19M
Debt
$2B
Debt (1980): $19M, investors not publicly disclosed
Debt (2022): $2B led by Citigroup
Key Investors in Amgen
Citigroup
Citigroup Inc. is a leading global financial services company providing a broad range of financial products and services. As a major bank, it likely offers corporate and investment banking services, including financing and advisory for large-scale enterprise operations.
What's next for Amgen?
With a substantial total funding history of $2B and a recent strategic investment of $2B, Amgen is well-positioned for continued leadership in the biotechnology arena. The company's focus on innovation, coupled with its established market presence, suggests future endeavors will likely involve expanding its therapeutic pipeline, exploring new technological platforms, and potentially engaging in strategic partnerships or acquisitions to further its global reach and impact. The enterprise-level nature of its financing points towards significant expansion and continued investment in groundbreaking research.
See full Amgen company page
